We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
Read MoreHide Full Article
BioLife Solutions, Inc. (BLFS - Free Report) , a key player in bioproduction tools and services for cell and gene therapy (CGT) and the broader biopharma market, has unveiled its latest innovation, CryoCase, at the International Society for Cell & Gene Therapies (ISCT) event in Vancouver, Canada.
This latest addition to the company’s CellSeal product line is set to be released to CGT developers in August and is currently available for demonstration.
More on CryoCase
CryoCase is the first cryo-compatible rigid container designed for closed-system fill and retrieval of larger volumes of fluid, up to 75mL. Its transparent design enables improved compliance with USP 790, USP 1790 and other international visible inspection methods.
Manufactured under stringent environmental and processing controls, CryoCase addresses the common issue of particulates in single-use disposable manufacturing. Early tests indicate that CryoCase offers comparable cell viability and recovery rates to existing storage bags and boasts a high resistance to leaks or fractures when subjected to frozen state drop testing.
Integration and Compatibility
Designed with volume versatility and a rigid, protective structure, CryoCase integrates seamlessly with existing systems, enhancing throughput and streamlining procedures. This innovation is compatible with various downstream processing systems, including BioLife's own Signata CT-5. This compatibility underscores CryoCase’s potential to reduce overall risks and costs in CGT manufacturing and distribution.
Image Source: Zacks Investment Research
Addressing Industry Challenges
The introduction of the CryoCase comes at a crucial time when particulates in reagent manufacturing and final drug products are increasingly problematic. By offering a better primary container and a true closed-system approach, BioLife Solutions aims to mitigate these risks, ultimately facilitating safer and more efficient production of life-saving therapies.
Market Prospect
According to a BCC Research report, the global market for cell and gene therapy tools and reagents is estimated to reach $13.7 billion in 2027 from $8.3 billion in 2022, at a CAGR of 10.6%.
Share Price Performance
Year to date, shares of BLHS have surged 33.9% compared with the industry’s 2% growth.
Hims & Hers Heath stock has surged 127.9% in the past year. Estimates for the company’s earnings have risen from 11 cents to 18 cents for 2024 and from 25 cents to 33 cents for 2025 in the past 30 days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $11.23 in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 4.5% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
Estimates for ResMed’s fiscal 2024 earnings per share have moved to $7.64 from $7.59 in the past 30 days. Shares of the company have decreased 0.7% in the past year against the industry’s rise of 2.9%.
RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
BioLife Solutions, Inc. (BLFS - Free Report) , a key player in bioproduction tools and services for cell and gene therapy (CGT) and the broader biopharma market, has unveiled its latest innovation, CryoCase, at the International Society for Cell & Gene Therapies (ISCT) event in Vancouver, Canada.
This latest addition to the company’s CellSeal product line is set to be released to CGT developers in August and is currently available for demonstration.
More on CryoCase
CryoCase is the first cryo-compatible rigid container designed for closed-system fill and retrieval of larger volumes of fluid, up to 75mL. Its transparent design enables improved compliance with USP 790, USP 1790 and other international visible inspection methods.
Manufactured under stringent environmental and processing controls, CryoCase addresses the common issue of particulates in single-use disposable manufacturing. Early tests indicate that CryoCase offers comparable cell viability and recovery rates to existing storage bags and boasts a high resistance to leaks or fractures when subjected to frozen state drop testing.
Integration and Compatibility
Designed with volume versatility and a rigid, protective structure, CryoCase integrates seamlessly with existing systems, enhancing throughput and streamlining procedures. This innovation is compatible with various downstream processing systems, including BioLife's own Signata CT-5. This compatibility underscores CryoCase’s potential to reduce overall risks and costs in CGT manufacturing and distribution.
Image Source: Zacks Investment Research
Addressing Industry Challenges
The introduction of the CryoCase comes at a crucial time when particulates in reagent manufacturing and final drug products are increasingly problematic. By offering a better primary container and a true closed-system approach, BioLife Solutions aims to mitigate these risks, ultimately facilitating safer and more efficient production of life-saving therapies.
Market Prospect
According to a BCC Research report, the global market for cell and gene therapy tools and reagents is estimated to reach $13.7 billion in 2027 from $8.3 billion in 2022, at a CAGR of 10.6%.
Share Price Performance
Year to date, shares of BLHS have surged 33.9% compared with the industry’s 2% growth.
Zacks Rank and Key Picks
BioLife carries a Zacks Rank #4 (Sell) currently.
Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS - Free Report) , Medpace (MEDP - Free Report) and ResMed (RMD - Free Report) . While Hims & Hers Health and Medpace sport a Zacks Rank #1 (Strong Buy) each, ResMed carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks Rank #1 stocks here.
Hims & Hers Heath stock has surged 127.9% in the past year. Estimates for the company’s earnings have risen from 11 cents to 18 cents for 2024 and from 25 cents to 33 cents for 2025 in the past 30 days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $11.23 in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 4.5% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
Estimates for ResMed’s fiscal 2024 earnings per share have moved to $7.64 from $7.59 in the past 30 days. Shares of the company have decreased 0.7% in the past year against the industry’s rise of 2.9%.
RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.